Jean-Charles Soria: Cancer Cachexia – A Lethal, Underdiagnosed Syndrome
Jean-Charles Soria, SVP and Oncology Therapeutic Area Head at Amgen, shared a post on LinkedIn about a paper by Kexin Koh et al. published in Cancer Discovery:
“Cancer cachexia = an underdiagnosed, lethal syndrome.
- Affects up to 80% in pancreatic CA, 40% in lung.
- It’s not just weight loss – think systemic inflammation, altered metabolism, fat/muscle wasting.
- GDF-15, IL-6, activin A are key molecular drivers.
- A major unmet need in cancer patients.”
Amy C. Moore, Director, Patient Engagement and Advocacy at Summit Therapeutics, shared this post, adding:
“I am honored to be part of Team CANCAN, funded by Cancer Grand Challenges, to understand the causes of and find new interventions for cancer cachexia. Learn more about Team CANCAN’s work: CANCAN | Cancer Grand Challenges.”
Title: Cancer-Associated Cachexia: Bridging Clinical Findings with Mechanistic Insights in Human Studies
Authors: Kexin Koh, Rachel Scott, Elizabeth M. Cespedes Feliciano, Tobias Janowitz, Marcus D. Goncalves, Eileen P. White, Barry J.A. Laird, Kerstin Haase, Mariam Jamal-Hanjani
You can read the Full Article on Cancer Discovery.
More posts featuring Jean-Charles Soria and Amy C. Moore.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023